Sugi Predict

Sugi Predict / Compounds / SCHEMBL3153231

SCHEMBL3153231

SCHEMBL3153231

O=S(=O)(Cl)c1ccc2scnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 2/20 0.43
▸ KDR P35968 1/20 0.43
▸ GLRA3 O75311 1/20 0.43
▸ GLRB P48167 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ PIK3CD O00329 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ OGA O60502 3/20 0.41
▸ RIPK1 Q13546 1/20 0.41
▸ RIPK3 Q9Y572 1/20 0.41
▸ SPPL2A Q8TCT8 1/20 0.39
▸ CHRM5 P08912 4/20 0.39
▸ PKM P14618 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL742714 0.86 ALDH1A1 (0.50) ALDH1A1HSD17B10RIPK1CHRM5PKM
SCHEMBL11516564 0.82 RIPK2 (0.59) RIPK2KDRGLRA3GLRBALDH1A1
SCHEMBL6466331 0.82 CHRM5 (0.44) RIPK2KDRGLRA3GLRBALDH1A1
SCHEMBL4710033 0.82 RXFP1 (0.47) RIPK2KDRGLRA3GLRBALDH1A1
Zinc Ion SCHEMBL7599075 0.82 RIPK2 (0.43) RIPK2KDRGLRA3GLRBALDH1A1
Hydrochloric Acid SCHEMBL27810068 0.81 CHRM5 (0.43) RIPK2KDRGLRA3GLRBALDH1A1
SCHEMBL6781759 0.80 ALDH1A1 (0.46) ALDH1A1HSD17B10RIPK1CHRM5PKM
SCHEMBL8371819 0.78 IKBKB (0.48) RIPK2KDRALDH1A1HSD17B10PIK3CD
SCHEMBL3307837 0.73 CA2 (0.50) RIPK2KDRPIK3CD
SCHEMBL3305480 0.73 RIPK2 (0.51) RIPK2KDRALDH1A1PIK3CDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136770-A 3-Aryl-4-sulfonyl-1, 3,4, 5-tetrahydrobenzo [ cd ] -indole compound, preparation method and application thereof 遵义医科大学 2025-06-13 — — CN disclosed
WO-2024217519-A1 PYRROLE SULFONYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 天地恒一制药股份有限公司 2024-10-24 — — WO disclosed
WO-2023150526-A1 COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY (US) 2023-08-10 — — WO disclosed
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2023-06-15 — — US disclosed
EP-2828238-B1 SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES ADAMED SP ZOO (PL) 2016-05-25 — — EP disclosed
CN-104220421-A Sulfonamide derivatives of benzylamine for the treatment of central nervous system disorders ADAMED SP ZOO 2014-12-17 — — CN disclosed
US-20140135310-A1 SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES ADAMED SP. Z O.O. (PL) 2014-05-15 — — US disclosed
CN-103649077-A Sulfonamide derivatives of cycloaliphatic amines for the treatment of central nervous system disorders ADAMED SP ZOO 2014-03-19 — — CN disclosed
EP-2233493-A1 Macrolides Pfizer Products Inc. (US) 2010-09-29 — — EP disclosed
CN-101801194-A Has 5-HT 63 ' the compound that replaces of receptor affinity MEMORY PHARM CORP 2010-08-11 — — CN disclosed
WO-2010024980-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 — — WO disclosed
EP-1836211-B1 MACROLIDES PFIZER PROD INC (US) 2010-03-03 — — EP disclosed
WO-2010021797-A1 CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-25 — — WO disclosed
US-20090069337-A1 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2009-03-12 — — US disclosed
WO-2009023844-A2 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2009-02-19 — — WO disclosed
US-7462600-B2 Macrolides PFIZER INC (US) 2008-12-09 — — US disclosed
EP-1836211-A1 MACROLIDES Pfizer Products Incorporated (US) 2007-09-26 — — EP disclosed
WO-2006067589-A1 MACROLIDES PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO disclosed
US-20060135447-A1 Macrolides CHUPAK LOUIS S 2006-06-22 — — US disclosed
WO-1999029670-A2 AMINOCARBONYLTETRALIN AND DIHYDRONAPHTALENE DERIVATES AS THROMBIN INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069337-A1 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR3A, HTR3B RIPK2 3893/4885KDR 568/4885GLRA3 103/4885
US-20060135447-A1 Macrolides LCAT, NOP2, HDAC6 RIPK2 3220/4885KDR 4882/4885GLRA3 3452/4885
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 CHRM5, CHRM1, CHRM2 RIPK2 2184/4885KDR 1965/4885GLRA3 156/4885
US-20140135310-A1 SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES DDC, INA, SCN5A RIPK2 2367/4885KDR 3884/4885GLRA3 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.